BPC-157 for IBD: What the Evidence Actually Shows

BPC-157 and GI Disease

Phase II trial completed

BPC-157 (as PL 14736) completed a Phase II trial for ulcerative colitis, but results were never published in a peer-reviewed journal. The animal data spans 30+ years.

Sikiric et al., Current Medicinal Chemistry, 2012

Sikiric et al., Current Medicinal Chemistry, 2012

View as image

BPC-157 originated from gastric juice research. It was isolated as a protective factor in human stomach secretions in the early 1990s, and its first documented effects were gastrointestinal: healing stomach ulcers, protecting gut mucosa, and reducing intestinal inflammation in rats.^[6] This GI origin story is what led a Croatian pharmaceutical company (Pliva) to advance BPC-157 into clinical trials for inflammatory bowel disease (IBD), specifically ulcerative colitis, under the drug designation PL 14736. That trial completed Phase II. The results were never published. This makes IBD simultaneously the strongest and weakest case for BPC-157: the strongest because the peptide was literally discovered in the organ system it would be treating, with decades of supporting animal data; the weakest because the one chance to generate human evidence ended in silence. For the broader BPC-157 story, see the cluster pillar.

The Phase II trial that disappeared

The most significant fact about BPC-157 and IBD is that a Phase II clinical trial happened and the results were never fully published.

Pliva, a Croatian pharmaceutical company (later acquired by Barr Pharmaceuticals, then Teva), developed BPC-157 under multiple designations: PL-10, PLD-116, and ultimately PL 14736. They conducted a Phase I safety study in healthy volunteers, presented by Veljaca et al. (2003) at Digestive Disease Week and published as a conference abstract in Gut, which showed the peptide was safe and well tolerated.^[1]

Ruenzi et al. then conducted a multicenter, randomized, double-blind, placebo-controlled Phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis. This study was also presented at a gastroenterology conference. The trial design was rigorous by any standard: multicenter, randomized, double-blind, placebo-controlled. These are the gold-standard elements of clinical trial methodology.

But the full results were never published in a peer-reviewed journal. No manuscript appeared in Gastroenterology, Gut, Lancet, or any other outlet where such a trial would typically be reported. The reasons for this non-publication are not publicly documented. Possible explanations range from negative results (the most common reason trials go unpublished) to corporate restructuring during Pliva's acquisition, to regulatory or commercial decisions unrelated to efficacy.

This non-publication is the single most consequential gap in BPC-157 research. A positive Phase II result would have positioned BPC-157 as a legitimate IBD therapeutic candidate with a clear path to Phase III. A negative result would have provided equally valuable data: evidence that the peptide does not work in human IBD despite decades of animal support. Either way, the data exists somewhere. Its absence from the scientific literature leaves the field stuck between promising preclinical evidence and a clinical question mark. The ghost trial is covered in detail in a dedicated article.

Animal colitis models: what has been tested

Despite the clinical trial gap, the animal evidence for BPC-157 in colitis models is extensive.

TNBS-induced colitis. Duzel et al. (2017) published the most comprehensive single study in World Journal of Gastroenterology. They tested BPC-157 in trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats, a standard model that produces transmural inflammation resembling Crohn's disease. BPC-157, applied as a bath to the blood-deprived colon segment, improved vessel presentation as documented by USB microscope camera. They also tested colonic ischemia and reperfusion, showing BPC-157 reduced oxidative stress markers (MDA levels increased in ischemic rats; BPC-157 counteracted this) and modulated NO levels (decreased in ischemia; increased in reperfusion; BPC-157 normalized both directions). The study demonstrated BPC-157's effects were tied to the NO system through co-administration with L-NAME and L-arginine, consistent with the broader NO-system evidence.^[3]

Cysteamine-induced colitis. Klicek et al. (2013) tested BPC-157 in cysteamine-induced colitis, a model that produces lesions similar to ulcerative colitis. BPC-157 healed the colitis and simultaneously improved colon-colon anastomosis healing. They also demonstrated that BPC-157 counteracted cuprizone-induced brain injuries and motor disability in the same study, linking GI healing to brain-gut axis effects.^[4]

DSS-induced colitis. Several studies from the Zagreb group have tested BPC-157 in dextran sodium sulfate (DSS) models, which produce superficial mucosal inflammation closer to ulcerative colitis. The consistent finding is reduction in macroscopic damage scores, improved histological outcomes, and modulation of inflammatory markers.

Colonic ischemia-reperfusion. This model mimics the vascular component of IBD, where mucosal blood flow impairment contributes to inflammation. Duzel et al. (2017) showed BPC-157 improved vessel presentation during both ischemia and reperfusion phases, with effects tied to normalization of NO and reduction of oxidative stress.^[3]

Fistula healing: the surgical IBD connection

One of the most distinctive features of BPC-157's GI research is its consistent effect on fistula healing. Fistulas are abnormal connections between two body surfaces, and they are a major complication of Crohn's disease. Standard treatment often requires surgery, and recurrence rates are high.

Klicek et al. (2008) demonstrated BPC-157 healed colocutaneous fistulas in rats, with the healing directly tied to the NO system. The study used the formal drug designation "PL14736, in clinical trials as a therapy for inflammatory bowel disease" in its title, explicitly connecting the animal fistula research to the clinical IBD program.^[7]

Subsequent studies showed BPC-157 healing additional fistula types: rectovaginal (Baric et al., 2016), vesicovaginal (Rasic et al., 2021), esophagocutaneous (Cesarec et al., 2013), duodenocutaneous (Skorjanec et al., 2015), gastrocutaneous (Skorjanec et al., 2009), colovesical (Grgic et al., 2016), and duodenocolic (Vukusic et al., 2024). The consistency across fistula types suggests a general wound healing mechanism rather than tissue-specific pharmacology.

For IBD, the fistula data is clinically relevant because perianal and enteric fistulas are among the most debilitating complications of Crohn's disease. Current treatments (anti-TNF biologics, surgical drainage, setons) have variable success rates and high recurrence. A compound that heals experimental fistulas across multiple anatomical locations would address a genuine unmet need, if it works in humans.

Anastomotic healing: post-surgical IBD application

IBD patients frequently require surgical resection of diseased bowel segments. The anastomosis (surgical reconnection point) is vulnerable to leaking, infection, and failure. Anastomotic leak rates in IBD surgery range from 3-15% depending on the location and disease activity.

Vuksic et al. (2007) showed BPC-157 healed ileoileal anastomosis in rats, the same type of surgical connection created during small bowel resection for Crohn's disease. The study explicitly referenced BPC-157's IBD clinical trial designations (PL-10, PLD-116, PL14736).^[2]

Djakovic et al. (2016) extended this to esophagogastric anastomosis, showing improved healing with BPC-157 and L-arginine and impaired healing with L-NAME, linking the anastomotic benefit to NO-system modulation.^[8]

The anastomosis data has a clearer translational path than the colitis data because the endpoint is objective (leak rate, burst pressure, histological healing) and the clinical need is acute and surgical rather than chronic and immunological.

Intestinal permeability: the barrier function mechanism

Park et al. (2020) published one of the more mechanistically detailed studies, examining BPC-157's effect on NSAID-induced intestinal permeability disruption. NSAIDs damage the GI tract partly by increasing intestinal permeability (the "leaky gut" mechanism), which allows bacterial translocation and triggers inflammation.

BPC-157 stabilized intestinal permeability and enhanced cytoprotection against NSAID cytotoxicity in both cell cultures and animal models. The study proposed that BPC-157 acts as a cytoprotective agent that maintains epithelial barrier function, preventing the cascade from barrier disruption to inflammation that characterizes both NSAID injury and IBD.^[5]

This is relevant to IBD because barrier dysfunction is a recognized feature of both Crohn's disease and ulcerative colitis. Increased intestinal permeability precedes clinical flares and may contribute to disease initiation. If BPC-157 maintains barrier integrity, it could theoretically prevent the inflammatory cascade before it begins, rather than suppressing it after the fact (as current biologics do). How BPC-157 protects the gut lining is covered in a dedicated article. The leaky gut evidence is examined separately.

The cytoprotection framework

Sikiric et al. (2012) published a focused review on BPC-157 and ulcerative colitis in Current Medicinal Chemistry. Their framework positions BPC-157 as a "cytoprotective agent" in the tradition of Robert's stomach cytoprotection concept: a compound that protects mucosal cells from injury through multiple converging mechanisms rather than through a single anti-inflammatory pathway.^[1]

The proposed mechanisms include: endothelial protection and angiogenesis (maintaining mucosal blood supply), NO-system modulation (controlling vasodilation and inflammation), growth factor interaction (promoting mucosal repair), and adaptive cytoprotection (the phenomenon where mild pre-injury exposure protects against subsequent major injury).

This multi-mechanism model distinguishes BPC-157 from current IBD drugs, which target specific inflammatory pathways: anti-TNF (infliximab, adalimumab), anti-integrin (vedolizumab), anti-IL-12/23 (ustekinumab), or JAK inhibition (tofacitinib). If BPC-157 works through general cytoprotection rather than specific immunosuppression, it might have a different side effect profile, but this is entirely speculative without human IBD trial data.

The 2011 review by Sikiric reinforced this position, characterizing BPC-157 as a "novel therapy in gastrointestinal tract" with effects spanning the entire GI tract from esophagus to colon, working through mechanisms that overlap with but are distinct from conventional antiulcer and anti-inflammatory agents.^[9]

What separates BPC-157 from approved IBD drugs

Current IBD therapeutics are immunosuppressive. They work by blocking specific inflammatory mediators (TNF-alpha, interleukins, integrins, JAK kinases) that drive the immune-mediated destruction of gut tissue. This approach is effective but carries risks: increased infection susceptibility, potential for malignancy with long-term use, and loss of response over time as patients develop antibodies against biologic drugs.

BPC-157's proposed mechanism is fundamentally different. It is not immunosuppressive. Instead, it appears to protect and repair the tissue that the immune system is attacking, while modulating the vascular and NO-mediated processes that support tissue integrity. In animal models, BPC-157 does not suppress immune function systemically; it heals the local tissue damage.

This distinction matters because IBD treatment has shifted toward early intervention and mucosal healing as primary endpoints. If a compound can promote mucosal healing through cytoprotection and vascular support rather than immunosuppression, it could potentially complement existing biologics rather than replace them. But this is a hypothesis based on animal mechanism data, not clinical trial evidence. The BPC-157 body protection compound overview provides broader context on the peptide's evidence base across all indications.

The evidence gap

The IBD case for BPC-157 is simultaneously one of the strongest and most frustrating in peptide research. The animal evidence is extensive, spanning multiple colitis models, fistula types, and anastomotic healing paradigms. The peptide originated from gastric juice, making the GI tract its natural therapeutic territory. A Phase II clinical trial was conducted with rigorous methodology.

And yet: the single most important data point, the Phase II trial result, remains unpublished. No IBD patient has received BPC-157 in a published clinical trial setting. The gap in human trial data is not unique to IBD but is felt most acutely here, where a completed trial exists that could resolve the question.

The cancer risk considerations are also relevant to IBD, because IBD patients have elevated colorectal cancer risk. A pro-angiogenic peptide administered to chronically inflamed colon tissue in patients with increased malignancy risk introduces additional safety questions that the preclinical data cannot address.

The gut-brain axis connection adds another dimension to the IBD discussion. Klicek et al. (2013) demonstrated simultaneous improvement in colitis and brain injury in the same animal model, consistent with the bidirectional gut-brain communication that is increasingly recognized as relevant to IBD pathophysiology.^[4]

The Bottom Line

BPC-157 has the deepest animal evidence base for IBD of any indication, spanning colitis models, fistula healing, anastomotic repair, and barrier function restoration across 30+ years. A Phase II clinical trial for ulcerative colitis (PL 14736) was completed but never published, leaving the single most important question unanswered: does it work in human IBD? Until those trial results surface or a new clinical program begins, BPC-157 for IBD remains the most data-rich yet clinically unvalidated peptide therapy in gastroenterology.

Frequently Asked Questions

Has BPC-157 been tested in humans for IBD?

A Phase II clinical trial of BPC-157 (as PL 14736 enema) for mild-to-moderate ulcerative colitis was completed by Pliva, a Croatian pharmaceutical company. The trial was multicenter, randomized, double-blind, and placebo-controlled. However, the full results were never published in a peer-reviewed journal. A Phase I safety study in healthy volunteers showed the peptide was safe and well tolerated.^[1]

Can BPC-157 help ulcerative colitis?

In animal models, BPC-157 reduces colitis severity in TNBS, cysteamine, and DSS models, heals colocutaneous fistulas, and stabilizes intestinal permeability. A Phase II trial for human ulcerative colitis was conducted but results were never published. Without published human data, whether BPC-157 helps ulcerative colitis in humans is unknown.^[3]

Does BPC-157 heal gut inflammation?

In rat models, BPC-157 reduces macroscopic colon damage scores, decreases oxidative stress markers, normalizes nitric oxide levels, and improves histological outcomes in colitis. These effects are mediated through the NO system and cytoprotective mechanisms rather than immunosuppression. No human inflammation data have been published.^[3]

What happened to the BPC-157 IBD clinical trial?

Pliva (later acquired by Barr/Teva) developed BPC-157 as PL 14736 and completed Phase I and Phase II trials for ulcerative colitis. The Phase I showed safety in healthy volunteers. The Phase II was a multicenter, randomized, placebo-controlled study. Neither trial's full results were published in a peer-reviewed journal. The reasons for non-publication are not publicly documented.^[1]

Is BPC-157 better than biologics for IBD?

No comparison exists. BPC-157 has never been tested alongside biologics (infliximab, adalimumab, vedolizumab, ustekinumab) in any study. The proposed mechanisms differ fundamentally: biologics suppress specific inflammatory pathways while BPC-157 appears to work through cytoprotection and vascular support. Without human trial data, no efficacy comparison can be made.^[9]

Can BPC-157 heal fistulas from Crohn's disease?

In rat models, BPC-157 has healed colocutaneous, rectovaginal, vesicovaginal, esophagocutaneous, gastrocutaneous, colovesical, and duodenocolic fistulas. Perianal and enteric fistulas are major complications of Crohn's disease. No human fistula study has been conducted with BPC-157, despite this being one of the strongest areas of preclinical evidence.^[7]